Targeting vascular endothelial growth factor in renal cell carcinoma.
Renal cancer is the most lethal of all urological malignancies with overall 5-year survival rates of around 60%. The predominant reason for the poor prognosis of this cancer has been the relative lack of effective systemic therapy for advanced metastatic disease. Until recently immunotherapy with in...
मुख्य लेखकों: | Patel, N, Muneer, A, Blick, C, Arya, M, Harris, A |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
2009
|
समान संसाधन
-
Vascular endothelial growth factor expression in renal cell carcinoma
द्वारा: Mohtarrudin, Norhafizah, और अन्य
प्रकाशित: (2018) -
Renal damage associated with anti-vascular endothelial growth factor treatment
द्वारा: Pradeep K Panigrahi, और अन्य
प्रकाशित: (2024-01-01) -
Sirolimus Toxicity and Vascular Endothelial Growth Factor Release From Islet and Renal Cell Lines
द्वारा: Laugharne, M, और अन्य
प्रकाशित: (2007) -
Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
द्वारा: Brown, J, और अन्य
प्रकाशित: (2024) -
Vascular endothelial growth factor expression in lung cancer.
द्वारा: O'Byrne, K, और अन्य
प्रकाशित: (1998)